Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 76 of 10353 for:    Anti-Infective Agents AND Bacterial

In-vivo Efficacy of Patient Preoperative Prep

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02831998
Recruitment Status : Completed
First Posted : July 13, 2016
Last Update Posted : July 27, 2018
Sponsor:
Information provided by (Responsible Party):
Zurex Pharma, Inc.

Brief Summary:
The objective of the study is to demonstrate the antimicrobial efficacy of the ZP Preoperative Prep on skin flora of the abdomen and inguinal regions of human subjects.

Condition or disease Intervention/treatment Phase
Surgical Skin Preparation Drug: ZuraPrep Drug: ChloraPrep Drug: ZP Vehicle Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 690 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZP
Actual Study Start Date : July 27, 2016
Actual Primary Completion Date : April 9, 2017
Actual Study Completion Date : April 9, 2017


Arm Intervention/treatment
Experimental: ZP (70% IPA)
Isopropyl alcohol (IPA) 70%
Drug: ZuraPrep
Apply topically.
Other Names:
  • Isopropyl alcohol 70%
  • ZP

Active Comparator: ChloraPrep
Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
Drug: ChloraPrep
Apply topically.
Other Names:
  • CHG 2%/IPA 70%
  • Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Placebo Comparator: ZP Vehicle
ZP without IPA
Drug: ZP Vehicle
Apply topically.




Primary Outcome Measures :
  1. Bacterial reduction [ Time Frame: 10 minutes post product application ]
    A 2-log per cm2 bacterial reduction on the abdomen region and a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.


Secondary Outcome Measures :
  1. Skin Irritation [ Time Frame: 30 seconds to 6 hours ]
    Safety as assessed by Skin Irritation score (erythema, edema, rash, dryness) of 0-3.

  2. Bacterial reduction [ Time Frame: 30 seconds post product application ]
    A 2-log per cm2 bacterial reduction on the abdomen region and a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.

  3. Bacterial reduction [ Time Frame: 6 hours post product application ]
    Skin flora does not return to baseline on the abdomen and inguinal region is consider a success.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects of any race
  • Subjects in good health
  • Minimum skin flora baseline requirements on abdomen and groin
  • Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder near or on the applicable test area.

Exclusion Criteria:

  • Topical or systemic antimicrobial exposure within 14 days prior to screening and treatment days, including antibiotics.
  • Subjects with a history of skin sensitivity, skin allergies, or skin cancer.
  • Subjects who are pregnant, attempting pregnancy or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02831998


Locations
Layout table for location information
United States, Virginia
MicroBioTest Laboratories
Sterling, Virginia, United States, 20164
Sponsors and Collaborators
Zurex Pharma, Inc.

Layout table for additonal information
Responsible Party: Zurex Pharma, Inc.
ClinicalTrials.gov Identifier: NCT02831998     History of Changes
Other Study ID Numbers: ZX-ZP-0073 / 865-105
First Posted: July 13, 2016    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Ethanol
Chlorhexidine
Chlorhexidine gluconate
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Disinfectants
Dermatologic Agents